Evolocumab and Alirocumab, as PCSK9 inhibitors, have been approved for the clinical treatment of hyperlipidemia in many countries and regions (108, 109), but their actual effects on AAA have not been tested in clinical studies. This evidence concerns the gene PCSK9 and triple-A syndrome.